Regeneron Pharmaceuticals (REGN) shares have dipped over 11% year-to-date, including a 5% drop following the release of its first-quarter earnings, which surpassed expectations. The decline is largely attributed to a 10% drop in sales of Eylea, its leading eye therapy, due to competition from Roche’s Vabysmo. Despite this, the company reported a 19% increase in total revenue, reaching $3.6 billion, and announced a new $3 billion share repurchase program, signaling confidence in its financial health.

The mixed earnings report highlights Regeneron’s robust pipeline, with over 50 therapies in development, including promising growth in cancer treatment Libtayo and Dupixent, which reported a 36% increase in sales. The recent FDA approval of Otarmeni, a gene therapy for hearing loss, adds to its innovative portfolio, though offered for free in the U.S. as part of a strategic pricing agreement.

For market professionals, Regeneron’s current P/E ratio of approximately 16.5 appears attractive given its growth trajectory, suggesting that the recent stock price drop may present a buying opportunity amidst strong fundamentals and a diverse pipeline.

Source: fool.com